SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4663-4665. Prepublished online as a Blood First Edition Paper on February 14, 2006; DOI 10.1182/blood-2005-11-4728. This Article Full Text (PDF) All Versions of this Article: 2005-11-4728v1 107/12/4663    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nagayama, J. Articles by Ishii, E. Search for Related Content PubMed PubMed Citation Articles by Nagayama, J. Articles by Ishii, E. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 29, 2005 Accepted February 3, 2006 Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group Jun Nagayama, Daisuke Tomizawa, Katsuyoshi Koh, Yoshihisa Nagatoshi, Noriko Hotta, Tomoko Kishimoto, Yoshihiro Takahashi, Tomoko Kuno, Kanji Sugita, Takashi Sato, Kohji Kato, Atsushi Ogawa, Tatsutoshi Nakahata, Shuki Mizutani, Keizo Horibe, and Eiichi Ishii* Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan Department of Pediatrics, University of Tokyo, Tokyo, Japan Department of Pediatrics, Yamaguchi University, Yamaguchi, Japan Department of Pediatrics, Nara Medical University, Nara, Japan Department of Pediatrics, Hirosaki University, Hirosaki, Aomori, Japan Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan Department of Pediatrics, University of Yamanashi, Tamaho, Yamanashi, Japan Department of Pediatrics, Hiroshima University, Hiroshima, Japan Division of Pediatric Hematology/Oncology, Nagoya Red Cross 2nd Hospital, Nagoya, Japan Division of Pediatrics, Niigata Cancer Center Niigata Hospital, Niigata, Japan Department of Pediatrics, Kyoto University, Kyoto, Japan Clinical Research Center, National Nagoya Hospital, Nagoya, Japan Department of Pediatrics, Saga University, Saga, Japan * Corresponding author; email: ishiei{at}med.saga-u.ac.jp. Although infants with acute lymphoblastic leukemia (ALL) and a germline MLL gene have a better prognosis than comparable infants with a rearranged MLL gene, their optimal therapy is controversial. In two consecutive studies, conducted between 1996 and 2002, we treated 22 cases of infant ALL with germline MLL using chemotherapy alone. The 5-year event-free survival rate was 95.5% with a 95% confidence interval of 86.9-100%. All 21 infants with precursor B-cell ALL have been in first complete remission for 3.5 to 8.8 years. Most treatment-related toxicities were predictable and well tolerated, and neither secondary malignancies nor physical growth impairments have been observed. These results indicate that chemotherapy of the type described here is both safe and highly effective against infant precursor B-cell ALL with MLL in the germline configuration. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Two tales of infant leukemia Ching-Hon Pui Blood 2006 107: 4576-4577. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020